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Amiodarone Use and All-Cause Mortality
in Patients With a Continuous-Flow Left
Ventricular Assist Device
Rakesh Gopinathannair , MD, MA; Naga Venkata K. Pothineni, MD; Jaimin R. Trivedi, MD, MPH;
Henri Roukoz , MD; Jennifer Cowger, MD; Mustafa M. Ahmed , MD; Adarsh Bhan, MD;
Ashwin K. Ravichandran , MD; Geetha Bhat, MD; Amin Al Ahmad , MD; Andrea Natale , MD;
Luigi Di Biase , MD; Mark S. Slaughter , MD; Dhanunjaya Lakkireddy , MD
BACKGROUND: Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with
amiodarone being the most commonly used antiarrhythmic drug in continuous-flow left ventricular assist device (CF-LVAD)
recipients. The purpose of this study was to assess the impact of amiodarone use on long-term all-cause mortality in ptients
with a CF-LVAD.
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METHODS AND RESULTS: A retrospective multicenter study of CF-LVAD was conducted at 5 centers including all CF-LVAD
implants from 2007 to 2015. Patients were stratified based on pre–CF-LVAD implant amiodarone use. Additional use of amiodarone after CF-LVAD implantation was also evaluated. Primary outcome was all-cause mortality during long-term follow-up.
Kaplan-Meier curves were used to assess survival outcomes. Multivariable Cox regression was used to identify predictors
of outcomes. Propensity matching was done to address baseline differences. A total of 480 patients with a CF-LVAD (aged
58±13 years, 81% men) were included. Of these, 170 (35.4%) were on chronic amiodarone therapy at the time of CF-LVAD
implant, and 310 (64.6%) were not on amiodarone. Rate of all-cause mortality over the follow-up period was 32.9% in the
amiodarone group compared with 29.6% in those not on amiodarone (P=0.008). Similar results were noted in the propensity-
matched group (log-rank, P=0.04). On multivariable Cox regression analysis, amiodarone use at baseline was independently
associated with all-cause mortality (hazard ratio, 1.68 [95% CI, 1.1–2.5]; P=0.01).
CONCLUSIONS: Amiodarone use was associated with significantly increased rates of all-cause mortality in CF-LVAD recipients.
Earlier interventions for arrhythmias to avoid long-term amiodarone exposure may improve long-term outcomes in CF-LVAD
recipients and needs further study.
Key Words: amiodarone ■ arrhythmias ■ left ventricular assist device ■ mortality

A

miodarone is a commonly used antiarrhythmic
drug for suppressing atrial arrhythmias (AAs)
and ventricular arrhythmias (VAs) in patients
with advanced heart failure (HF), including those with
continuous-
flow left ventricular assist devices (CF-
LVADs). Although effective, amiodarone use is associated with a high incidence (10% in 1 year to 50% with

long-term use) of both cardiac and extracardiac adverse
effects.1 In patients with advanced HF, antiarrhythmic
drug options are limited, and amiodarone remains the
most frequently used drug despite prior studies showing no significant improvement in long-term outcomes.2
In a recent analysis of the INTERMACS (Interagency
Registry for Mechanically Assisted Circulatory Support)
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CLINICAL PERSPECTIVE
What Is New?

• Amiodarone use for atrial and ventricular arrhythmias in patients with advanced heart failure with
continuous-flow left ventricular assist devices is
associated with increased all-cause mortality.
• Use of amiodarone before a continuous-
flow
left ventricular assist device is associated with
higher rates of death compared with initiation
of amiodarone after a continuous-flow left ventricular assist device.

What Are the Clinical Implications?

• These results should prompt a careful evaluation
of the risks and benefits of amiodarone use and
reconsideration of the management strategies for
atrial and ventricular arrhythmias in continuous-
flow left ventricular assist device recipients.

Nonstandard Abbreviations and Acronyms
AA
CF-LVAD
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LVAD
VA

atrial arrhythmia
continuous-flow left ventricular assist
device
left ventricular assist device
ventricular arrhythmia

database of LVAD recipients, amiodarone use was associated with significantly reduced long-term survival,
but further details on indications and timing of use was
not available.3 In addition, limited data are available on
the impact of amiodarone use before LVAD implantation on long-term clinical outcomes in patients with a
CF-LVAD. The purpose of the current study was to assess the impact of amiodarone use at baseline as well
as following LVAD implantation on clinical outcomes in
a multicenter CF-LVAD cohort.

METHODS
We conducted a multicenter, retrospective study including patients who underwent CF-LVAD implantation at 5
centers from 2007 to 2015. The study protocol, including complete waiver of informed consent, was approved
by the institutional review boards at all the centers. All
patients had CF-LVADs implanted either as a bridge-to-
transplantation or as destination therapy. Implanted CF-
LVADs included HeartMate II (Abbott Medical, Chicago,
IL) and HVAD (Medtronic, Minneapolis, MN). The data,
analytic methods, and study materials will not be made
available to other researchers for purposes of reproducing the results or replicating the procedure.

Amiodarone in Patients With an LVAD

Patients were divided into 2 groups based on pre-
LVAD implant chronic amiodarone use. Impact of pre-
LVAD amiodarone status on survival, hospitalizations,
and incidence of post-LVAD AA and VA were evaluated.
In patients who were on amiodarone before LVAD implant, we also evaluated whether continued post-LVAD
use of amiodarone was associated with adverse outcomes. Primary outcome of the study was all-cause
mortality. The day of the CF-LVAD implant marked the
start date for follow-up. The last day of follow-up was
the date of heart transplantation, CF-LVAD explantation, or date of death, whichever came first.

Statistical Analysis
Kaplan-Meier curves were used to assess survival outcomes, and the log-rank test was used to compare survival estimates. Multivariable Cox regression modeling
was used to identify predictors of outcomes. For the
multivariable Cox model, all baseline demographic and
clinical variables (reported in Table 1) were considered.
Those baseline variables with significant difference between groups, defined as P value <0.1, were included in
the multivariable Cox model. To further address the difference between the groups at baseline, we performed
propensity matching between the groups. We initially
generated a logistic regression model to identify propensity scores for individual patients based on their study
group. We then used the individual propensity scores to
perform a 1:1 matching of the patients. The final matched
cohort had 244 patients (122 in each group).

RESULTS
A total of 480 patients with a CF-
LVAD (aged
58±13 years, 81% men) were included. Two-thirds of
the patients were White, and about half had ischemic
cardiomyopathy. Median duration of LVAD support
was 479 days (interquartile range, 224–
965 days).
Of these 480 patients, 170 (35.4%) were on chronic
amiodarone therapy at the time of LVAD implant, and
310 (64.6%) were not on amiodarone. Baseline (before LVAD implant) characteristics of the patients in
the amiodarone and no-amiodarone groups are presented in Table 1. Patients who were on chronic amiodarone therapy were older (aged 60±12 years versus
57±14 years, P=0.01) and had a higher prevalence of
renal insufficiency (52% versus 39%, P=0.009). Rates
of AA were similar between the groups, but patients in
the amiodarone group had a higher prevalence of VA
(48% versus 30%, P=0.0001).

All-Cause Mortality
The rate of all-
cause mortality over the follow-
up period was 32.9% (n=56) in the amiodarone group compared with 29.6% (n=92) in those not on amiodarone.
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Table 1. Baseline Characteristics of the Study Population Stratified by Baseline Use of Amiodarone
Characteristic

No-amiodarone group, N=310

Amiodarone group, N=170

P value

Age, y

56.7±14.1

60.3±11.9

0.01

Male sex, %

79%

86%

0.06

White race, %

63%

67%

0.7

BMI, median, kg/m2

28.4

29.2

0.6

Nonischemic cardiomyopathy, %

50%

43%

0.06

Diabetes, %

42%

47%

0.27

Hypertension, %

65%

68%

0.4

CAD, %

56%

62%

0.2

CKD, %

39%

52%

0.009

Destination therapy, %

50%

53%

0.5

CRTD, %

50%

62%

0.009

Other antiarrhythmic drugs, %

5%

11%

0.02

β-blockers, %

85%

86%

0.6

PR, ms

159.6±43.2

157.5±49.2

0.8

QRS, ms

137.1±34.5

155.9±34.3

<0.0001

QTC, ms

513.7±60.9

532.2±67.5

0.002

PreVAD LVEF, %

16±6

16.4±6.7

0.7

PreVAD LVEDD, cm

7.1±1.0

7.1±1.0

0.9

PreVAD LVESD, cm

6.4±1.1

6.5+/−1.1

0.8

AA, %

57%

59%

0.6

VA, %

30%

48%

<0.0001

LVAD support, median, d

469

489

0.4
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AA indicates atrial arrhythmia; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CRTD, cardiac resynchronization therapy
defibrillator; LVAD, left ventricular assist device; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular
end-systolic diameter; VA, ventricular arrhythmias, and VAD, ventricular assist device.

Kaplan-
Meir survival analyses showed a significantly
higher rate of all-cause mortality (P=0.008) in patients
who were on amiodarone at the time of LVAD implantation (Figure 1).

Amiodarone Use After LVAD Implant
Among patients in the amiodarone group, the drug
was continued after LVAD implantation in 70%. In
patients not on amiodarone, it was started after
LVAD implantation in 36%. All-cause mortality based
on before and after LVAD implantation amiodarone
status is depicted in Figure 2. Patients in the amiodarone group who were continued on it after LVAD
implantation had higher rates of all-cause mortality
compared with those in whom it was discontinued
(log-rank P=0.03; Figure 2). Interestingly, patients
with amiodarone use before LVAD implantation had
higher mortality rates compared with those in whom
amiodarone was started after LVAD implantation.
Following LVAD implantation, patients in the amiodarone group continued to have a higher incidence
of VA (51% versus 37%, P=0.003; Table 2), but all-
cause and cardiac hospitalizations and incidence of
AA were comparable between the groups.

Predictors of Mortality
On multivariable Cox regression analysis accounting for age, baseline comorbidities, type of cardiac
implantable electronic device, before LVAD VAs, and
use of other antiarrhythmic medications, amiodarone
use at baseline was the only variable that was independently associated with all-cause mortality (hazard
ratio, 1.68 [95% CI, 1.1–2.5]; P=0.01; Table 3).

Propensity-Matched Cohort
A propensity-matched analysis was performed, matching 22 baseline demographic and clinical variables. The
matched cohort included 244 patients, 122 each in the
amiodarone and no-amiodarone group. There were no
baseline differences between the groups (Table 4). Kaplan-
Meier analysis showed that patients in the amiodarone
group had significantly lower survival when compared with
the no-amiodarone group (log-rank, P=0.04; Figure 3).

DISCUSSION
In this large multicenter cohort of patients with a CF-
LVAD, we report a significantly higher all-cause mortality among patients on chronic amiodarone therapy
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Figure 1. Kaplan-
Meier analysis showing increased all-
cause mortality during follow-
up
in patients with a left ventricular assist device stratified by use of amiodarone at baseline
(amiodarone group [1] vs no-amiodarone group [0]; log-rank, P=0.008).
VAD indicates ventricular assist device.
Downloaded from http://ahajournals.org by on July 21, 2022

before LVAD implantation. After adjusting for multiple
comorbidities and performing a propensity-matched
analysis, amiodarone use before LVAD implantation
was an independent predictor of death following CF-
LVAD implantation. Interestingly, amiodarone initiation
after LVAD implantation for new arrhythmias did not affect long-term mortality.
Despite a high incidence of VAs in patients with an
LVAD, data are limited in terms of optimal management strategies and are limited to small observational
studies. Most patients undergoing evaluation for durable long-
term mechanical support devices have
long-standing HF with significant adverse ventricular
remodeling that acts as an arrhythmic substrate. Both
AAs and VAs are commonly encountered in this population, with significant practice variation in management.
Pharmacological approaches to management of VAs in
this population with advanced HF is limited by concomitant comorbidities, drug interactions, and proarrhythmic and systemic side effects.4,5 Amiodarone remains
the most commonly used drug in this patient population because of all these factors and relatively benign
short-term side effects.6–9 Consistent with this general
practice, 48% of patients in the amiodarone group had
VA compared with 30% in the no-amiodarone group
in our cohort. Patients with pre-LVAD VAs have also
been shown to have a higher incidence of post-LVAD

VAs in prior studies, advocating for continued use of
implantable cardioverter-
defibrillator therapy in this
population.10–12 Even in our cohort, patients with pre-
LVAD VAs who were on amiodarone at baseline had
a higher incidence of post-LVAD VAs compared with
those without VAs at baseline.
Findings of our current study showing that
amiodarone use before LVAD implantation being an
independent risk factor for post-LVAD mortality should
provide pause to address optimal management of VAs
in patients with advanced HF progressing toward an
LVAD implant. These findings are in accordance with
other studies evaluating the effect of amiodarone in
end-stage HF populations undergoing LVAD implantation or heart transplantation.3,13,14 Catheter ablation
of VAs has emerged as a successful management
strategy for VAs, with multiple recent trials demonstrating safety and efficacy.15 However, existing data on efficacy of catheter ablation in patients with CF-LVADs
are limited to observational studies with variable outcomes.16 Pooled analysis of data from individual cohorts of LVAD VA ablation have shown that only a
quarter of the post-LVAD VAs are related to the surgical
cannula site, whereas the rest are secondary to preexisting cardiomyopathy substrate.16 Catheter ablation in
LVAD recipients is technically challenging. Approaches
to the left ventricle are often limited to transseptal
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Figure 2. Kaplan-Meier analysis of all-cause mortality in patients with a left ventricular assist
device (LVAD) stratified by before and after left ventricular assist device use of amiodarone (log-
rank, P=0.03).
(1) No amiodarone use before or after LVAD. (2) No amiodarone use before LVAD, was on amiodarone after
LVAD. (3) Amiodarone use at baseline (before LVAD); no amiodarone use after LVAD. (4) Amiodarone use
before and after LVAD. VAD indicates ventricular assist device.
Downloaded from http://ahajournals.org by on July 21, 2022

access, with careful attention to avoid the cannula
during catheter manipulation. Artifacts produced by
the LVAD also interfere with optimal electrocardiogram
interpretation. Given these limitations and the adverse
effects of long-term amiodarone therapy, whether early
catheter ablation of VAs in patients with advanced HF
being considered for potential LVAD therapy improves
outcomes needs to be studied.
Early primary prevention trials in patients with HF
have shown a reduction in arrhythmic mortality with
use of amiodarone, primarily in the era before the implantable cardioverter-
defibrillator. This benefit was
seen predominantly in patients with nonischemic

cardiomyopathy but did not translate to a reduction
in all-
cause mortality, likely because of nonarrhythmic deaths from drug toxicity.17,18 Even in these trials,
there was a hint toward worse outcomes with the use
of amiodarone in patients with advanced HF. For instance, in the SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial), patients with HF were allocated
to amiodarone versus implantable cardioverter-
defibrillator versus placebo and stratified by functional
class as a marker of HF severity. In functional class III
patients, amiodarone use was associated with a significant increase in mortality.19 Results of our study are in
alignment with these findings, with chronic amiodarone

Table 2. Incidence of Arrhythmias and Hospitalizations After Left Ventricular Assist Device Implantation in the Study
Population
Variable

No-amiodarone group,
N=310

Amiodarone group, N=170

P value

Post-VAD AA

55%

54%

0.9

Post-VAD VA

37%

51%

0.003

Total hospitalizations, median

3

2

0.65

No. of cardiac hospitalizations, median

1

1

0.61

Total hospitalization per 100 d of VAD support

0.52 (0.22–0.99)

0.62 (0.30–1.23)

0.08

Cardiac hospitalization per 100 d of VAD support

0.17 (0–0.44)

0.17 (0–0.45)

0.87

AA indicates atrial arrhythmia; VA, ventricular arrhythmia; and VAD, ventricular assist device.
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Table 3. Multivariable Cox Regression Analysis Evaluating
Predictors of Mortality
Parameter

Hazard ratio

Hazard ratio
confidence limits

P value

Age at implant

1.015

0.999

1.031

0.06

Sex, men=1,
women=2

1.297

0.813

2.069

0.27

CKD

1.243

0.855

1.807

0.25

ICD vs CRT

1.478

0.968

2.256

0.07

Other
antiarrhythmic

0.844

0.380

1.871

0.68

QRS

0.994

0.987

1.000

0.06

QTc

0.999

0.996

1.003

0.77

Amiodarone

1.683

1.129

2.508

0.01

β-blocker use

0.792

0.478

1.310

0.36

Pre-LVAD VA

1.196

0.793

1.804

0.39

CKD indicates chronic kidney disease; CRTD, cardiac resynchronization
therapy defibrillator; ICD, implantable cardioverter-
defibrillator; LVAD, left
ventricular assist device; and VA, ventricular arrhythmias.

use linked to higher mortality rates overall in patients
with advanced HF.
Another important finding in our study is that a quarter (27%) of patients in the amiodarone group had pre-
LVAD AAs only with no documented VAs. Management
Table 4.

of AAs, such as atrial fibrillation, in patients with HF is
limited by antiarrhythmic medication options, often necessitating use of amiodarone. Catheter ablation outcomes is an appealing alternative in these patients to
avoid long-term amiodarone use.20 Over the past few
years, multiple studies, including large randomized trials, have demonstrated a significant beneficial effect of
rhythm control with catheter ablation compared with
antiarrhythmic drugs, especially in patients with HF. In
the CASTLE-
AF (Catheter Ablation versus Standard
Conventional Therapy in Patients with Left Ventricular
Dysfunction and Atrial Fibrillation) trial, patients with HF
and left ventricular ejection fraction <35% were randomized to catheter ablation versus antiarrhythmic drugs for
management of atrial fibrillation. Patients randomized
to catheter ablation had a 38% overall reduction in the
primary outcome of death or HF hospitalization.21 In a
subanalysis, this benefit did not meet statistical significance in patients on amiodarone. Similar results of improved overall outcomes with catheter ablation for atrial
fibrillation in patients with HF have also been shown in the
CABANA (Catheter Ablation versus Antiarrhythmic Drug
Therapy for Atrial Fibrillation) trial.22 Given these data and
our current findings of worse long-term outcomes with
amiodarone use, early catheter ablation for AF in patients

Baseline Characteristics of the Propensity-Matched Cohort (n=244) Stratified by Baseline Use of Amiodarone
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Characteristic

No-amiodarone group,
N=122

Amiodarone group, N=122

P value

Age, y

63 (55–69)

62 (52–70)

0.71

Male sex, %

81%

86%

0.29

White race, %

60%

73%

0.07

BMI, median, kg/m2

28 (25–32)

28 (24–32)

0.28

Nonischemic cardiomyopathy, %

56%

55%

0.79

Diabetes, %

50%

45%

0.44

Hypertension, %

74%

68%

0.32

CAD, %

61%

60%

0.79

CKD, %

48%

46%

0.79

Destination therapy, %

48%

50%

0.84

CRTD, %

65%

63%

0.78

Other antiarrhythmic drugs, %

8%

9%

0.81

β-blockers, %

84%

84%

0.86

PR, ms

160 (120–190)

160 (128–180)

0.85

QRS, ms

158 (126–178)

156 (125–177)

0.95

QTC, ms

521 (490– 568)

539 (483– 579)

0.38

Pre-VAD LVEF, %

15 (11–20)

15 (12–18)

0.48

Pre-VAD LVEDD, cm

7.0 (6.4–7.7)

7.0 (6.3–7.7)

0.66

Pre-VAD LVESD, cm

6.3 (5.7–7.0)

6.4 (5.6–7.2)

0.86

AA, %

55%

54%

0.89

VA, %

65%

65%

1

LVAD support, median, d

526 (219–956)

494 (183–881)

0.4

AA indicates atrial arrhythmias; BMI indicates body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CRTD, cardiac resynchronization
therapy defibrillator; LVAD, left ventricular assist device; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end-systolic diameter; VA, Ventricular arrhythmias, and VAD, ventricular assist device.
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Figure 3. Kaplan-
Meier analysis showing increased all-
cause mortality during follow-
up in
the propensity-matched left ventricular assist device cohort stratified by use of amiodarone at
baseline (amiodarone group [1] vs no-amiodarone group [0]; log-rank, P=0.04).
VAD indicates ventricular assist device.
Downloaded from http://ahajournals.org by on July 21, 2022

with advanced HF being considered for an LVAD implant
could be a reasonable strategy and needs further study.
A common theme from most HF studies is that
any antiarrhythmic benefit of amiodarone is offset by
long-term drug toxicity. In a summary of trials studying
amiodarone for the primary prevention of sudden death,
pulmonary toxicity was seen in 2.9%, thyroid toxicity in
3.6%, and hepatic toxicity in 1.8%.23 A second issue
could be significant drug interactions with medications
such as digoxin and warfarin. A third factor to consider
is the effect of amiodarone on cardiac repolarization. In
our study, the amiodarone group had prolonged QTc
and QRS compared with the no-amiodarone group.
Whether additional amiodarone-induced QT prolongation increases further risk of VAs in this group is unclear.
Finally, chronic use of amiodarone has been shown to
increase defibrillation thresholds.4 Thus, any potential
benefits of amiodarone in patients with advanced HF
must be tempered against these potential risks.

Limitations
We acknowledge several limitations inherent to the retrospective nature of this study. Adjudication of cause of death
as arrhythmic versus nonarrhythmic was not available.
Data on other management strategies for VAs, such as use
of catheter ablation, were not available. Our findings need

confirmation in other populations. It is possible that patients
in the amiodarone group represented a sicker substrate
to begin with. However, no significant baseline difference
between groups in cardiomyopathy type, left ventricular dimensions, and LVAD indication was noted, and multivariable Cox regression analysis identified baseline amiodarone
use as an independent predictor of mortality. Moreover, the
results of the propensity-matched cohort of 244 patients,
which matched 22 baseline characteristics potentially contributing to increased sickness and frailty, also showed significantly reduced survival in the amiodarone group. Lastly,
unrecognized systemic toxicity as well as drug interactions,
in particular warfarin, in the post-
LVAD population may
have played a role.

CONCLUSIONS
In this large, multicenter CF-LVAD cohort, baseline use
of amiodarone was associated with reduced survival
after LVAD implantation. These findings should prompt
a reconsideration of the management strategy for AAs
and VAs in patients undergoing CF-LVAD implantation.
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